Breaking | HiDiamond's first innovative product was officially approved for clinical trials

On September 8, 2023, HiDiamond's first innovative product, HiD21 (a high‑specificity epigenetic therapeutic‑target inhibitor), received IND approval from the NMPA's Center for Drug Evaluation (CDE). Achieving IND-enabling studies, submission, and approval in just over a year highlights our professional expertise and operational efficiency.

HiD21 is a Class 1 innovative chemical drug. Systematic preclinical studies show that compared to all other investigational competitors, HiD21 offers superior pharmacodynamic and pharmacokinetic profiles with lower toxicity. It demonstrates strong potential clinical value in treating solid tumors, hematological malignancies, and autoimmune diseases, positioning it as a promising candidate for novel monotherapy and combination regimens.